Find opt in Xarelto leads of clients that have suffered from internal bleeding. Each Xarelto lead is hand selected for accuracy and your specific lawsuit filters. We pride ourselves on conversion and accuracy of our xarelto leads. Perfect for small or large law firms.
Xarelto Lead Generation
We offer Xarelto lead generation for attorneys. The internal U.S. qualification we use provides a more qualified lead than our competitors. The client must pass a Xarelto lead quality system to be deemed billable. Lead Canon can handle all of your mass tort and Xarelto lead generation with professionalism.
Mass Tort Leads
The best opt in mass tort leads are generated by Lead Canon. Our mass tort lead division focuses on quality opt in attorney leads. Each client is seeking a lawsuit evaluation and has been injured by a mass tort prescription drug.
Please complete our Xarelto lead request below.
Rivaroxaban (BAY 59-7939) is an oral anticoagulant invented and manufactured by Bayer; in a number of countries it is marketed as Xarelto. In the United States, it is marketed by Janssen Pharmaceutica. It is the first available orally active direct factor Xa inhibitor. Rivaroxaban is well absorbed from the gut and maximum inhibition of factor Xa occurs four hours after a dose. The effects last approximately 8–12 hours, but factor Xa activity does not return to normal within 24 hours so once-daily dosing is possible.
In those with non-valvular atrial fibrillation it appears to be as effective as warfarin in preventing nonhemorrhagic strokes and embolic events. Rivaroxaban is associated with lower rates of serious and fatal bleeding events than warfarin though rivaroxaban is associated with higher rates of bleeding in the gastrointestinal tract.
As with any anticoagulant the most serious adverse effect is bleeding, including severe internal bleeding.